| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 178 | 2023 | 823 | 28.640 |
Why?
|
| Antihypertensive Agents | 107 | 2023 | 285 | 20.440 |
Why?
|
| Blood Pressure | 96 | 2023 | 662 | 14.750 |
Why?
|
| Hyperaldosteronism | 38 | 2020 | 38 | 8.430 |
Why?
|
| Aldosterone | 37 | 2023 | 66 | 6.960 |
Why?
|
| Drug Resistance | 40 | 2019 | 97 | 6.030 |
Why?
|
| Sleep Apnea, Obstructive | 25 | 2022 | 56 | 5.020 |
Why?
|
| Spironolactone | 16 | 2023 | 36 | 4.280 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 25 | 2021 | 65 | 3.260 |
Why?
|
| Diuretics | 17 | 2019 | 51 | 2.760 |
Why?
|
| Medication Adherence | 10 | 2020 | 177 | 2.670 |
Why?
|
| Humans | 210 | 2023 | 42163 | 2.630 |
Why?
|
| Blood Pressure Determination | 21 | 2022 | 53 | 2.400 |
Why?
|
| Treatment Failure | 18 | 2020 | 61 | 2.100 |
Why?
|
| Sleep | 6 | 2020 | 179 | 2.040 |
Why?
|
| Middle Aged | 93 | 2023 | 11819 | 1.830 |
Why?
|
| Drug Therapy, Combination | 23 | 2020 | 233 | 1.810 |
Why?
|
| Risk Factors | 52 | 2020 | 3942 | 1.800 |
Why?
|
| Male | 116 | 2022 | 22779 | 1.790 |
Why?
|
| Sodium, Dietary | 9 | 2017 | 22 | 1.760 |
Why?
|
| Prevalence | 35 | 2020 | 1597 | 1.700 |
Why?
|
| Sympathetic Nervous System | 8 | 2019 | 64 | 1.650 |
Why?
|
| Female | 111 | 2022 | 24018 | 1.610 |
Why?
|
| Aged | 72 | 2020 | 7982 | 1.590 |
Why?
|
| Stroke | 11 | 2019 | 348 | 1.480 |
Why?
|
| Obesity | 16 | 2021 | 1131 | 1.470 |
Why?
|
| Hydrochlorothiazide | 6 | 2013 | 16 | 1.460 |
Why?
|
| Coronary Vasospasm | 6 | 2017 | 6 | 1.410 |
Why?
|
| Valine | 5 | 2013 | 29 | 1.390 |
Why?
|
| Tetrazoles | 5 | 2013 | 45 | 1.360 |
Why?
|
| Prospective Studies | 27 | 2023 | 1574 | 1.360 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 708 | 1.330 |
Why?
|
| Treatment Outcome | 30 | 2021 | 1586 | 1.320 |
Why?
|
| Practice Guidelines as Topic | 9 | 2020 | 225 | 1.290 |
Why?
|
| Sodium Chloride, Dietary | 5 | 2021 | 39 | 1.280 |
Why?
|
| Continuous Positive Airway Pressure | 6 | 2022 | 15 | 1.270 |
Why?
|
| Hypertension, Malignant | 3 | 2016 | 4 | 1.240 |
Why?
|
| Cardiovascular Diseases | 18 | 2018 | 729 | 1.220 |
Why?
|
| Amlodipine | 6 | 2016 | 20 | 1.200 |
Why?
|
| Disease Management | 5 | 2019 | 68 | 1.160 |
Why?
|
| alpha-Galactosidase | 3 | 2020 | 4 | 1.150 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2023 | 45 | 1.120 |
Why?
|
| Renin | 15 | 2020 | 31 | 1.100 |
Why?
|
| Adrenalectomy | 5 | 2020 | 23 | 1.070 |
Why?
|
| Drug Resistance, Multiple | 3 | 2012 | 28 | 1.030 |
Why?
|
| Adult | 53 | 2022 | 13458 | 1.020 |
Why?
|
| Coronary Artery Disease | 5 | 2019 | 164 | 1.010 |
Why?
|
| Ventricular Function, Left | 7 | 2022 | 111 | 1.000 |
Why?
|
| Renin-Angiotensin System | 9 | 2017 | 44 | 0.950 |
Why?
|
| Periodicals as Topic | 4 | 2019 | 51 | 0.940 |
Why?
|
| Renal Insufficiency, Chronic | 6 | 2021 | 188 | 0.940 |
Why?
|
| Prognosis | 14 | 2019 | 850 | 0.930 |
Why?
|
| Risk Assessment | 17 | 2021 | 845 | 0.900 |
Why?
|
| United States | 33 | 2021 | 5072 | 0.880 |
Why?
|
| Heart Failure | 5 | 2023 | 298 | 0.800 |
Why?
|
| Heart Ventricles | 4 | 2022 | 123 | 0.800 |
Why?
|
| Heart Rate | 11 | 2019 | 261 | 0.800 |
Why?
|
| Denervation | 3 | 2016 | 27 | 0.770 |
Why?
|
| Population Surveillance | 2 | 2014 | 245 | 0.760 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 3 | 2019 | 7 | 0.750 |
Why?
|
| Sodium | 9 | 2019 | 101 | 0.720 |
Why?
|
| Chlorthalidone | 4 | 2017 | 5 | 0.710 |
Why?
|
| Ambulatory Care | 2 | 2019 | 81 | 0.710 |
Why?
|
| Receptors, Mineralocorticoid | 3 | 2018 | 15 | 0.700 |
Why?
|
| Reserpine | 1 | 2020 | 2 | 0.680 |
Why?
|
| Fabry Disease | 1 | 2020 | 3 | 0.670 |
Why?
|
| Cardiac Volume | 2 | 2018 | 4 | 0.660 |
Why?
|
| Mutagenesis | 1 | 2020 | 92 | 0.660 |
Why?
|
| Follow-Up Studies | 12 | 2019 | 1051 | 0.650 |
Why?
|
| Weight Loss | 5 | 2015 | 138 | 0.650 |
Why?
|
| Wakefulness | 1 | 2020 | 23 | 0.650 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 135 | 0.650 |
Why?
|
| Circadian Rhythm | 9 | 2020 | 234 | 0.630 |
Why?
|
| Protein Multimerization | 1 | 2020 | 114 | 0.620 |
Why?
|
| Sleep Apnea Syndromes | 5 | 2019 | 27 | 0.610 |
Why?
|
| Metanephrine | 1 | 2019 | 1 | 0.610 |
Why?
|
| Diastole | 8 | 2023 | 47 | 0.600 |
Why?
|
| Life Style | 9 | 2020 | 326 | 0.600 |
Why?
|
| Retrospective Studies | 14 | 2022 | 2485 | 0.600 |
Why?
|
| Catecholamines | 1 | 2019 | 45 | 0.590 |
Why?
|
| Comorbidity | 11 | 2016 | 725 | 0.590 |
Why?
|
| Kidney | 5 | 2017 | 363 | 0.590 |
Why?
|
| Health Promotion | 2 | 2015 | 691 | 0.580 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2018 | 3 | 0.580 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 26 | 0.570 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2018 | 22 | 0.560 |
Why?
|
| Coronary Artery Bypass | 1 | 2018 | 47 | 0.560 |
Why?
|
| Primary Health Care | 2 | 2013 | 362 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 744 | 0.540 |
Why?
|
| 11-beta-Hydroxysteroid Dehydrogenase Type 2 | 1 | 2017 | 6 | 0.540 |
Why?
|
| Double-Blind Method | 14 | 2021 | 305 | 0.530 |
Why?
|
| Diagnostic Errors | 2 | 2017 | 21 | 0.530 |
Why?
|
| Coronary Disease | 2 | 2016 | 123 | 0.510 |
Why?
|
| Sleep Deprivation | 1 | 2016 | 29 | 0.510 |
Why?
|
| Atrial Fibrillation | 1 | 2018 | 121 | 0.500 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2016 | 70 | 0.490 |
Why?
|
| American Heart Association | 6 | 2021 | 21 | 0.480 |
Why?
|
| Endothelium, Vascular | 6 | 2021 | 261 | 0.470 |
Why?
|
| Cross-Sectional Studies | 10 | 2021 | 3077 | 0.460 |
Why?
|
| Awards and Prizes | 1 | 2015 | 28 | 0.450 |
Why?
|
| Diet, Sodium-Restricted | 3 | 2015 | 10 | 0.450 |
Why?
|
| Occupational Health Services | 1 | 2014 | 9 | 0.440 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2022 | 78 | 0.430 |
Why?
|
| Time Factors | 9 | 2020 | 1848 | 0.420 |
Why?
|
| Demography | 2 | 2014 | 195 | 0.420 |
Why?
|
| Patient Participation | 1 | 2014 | 87 | 0.400 |
Why?
|
| Myocardial Infarction | 4 | 2014 | 242 | 0.400 |
Why?
|
| Uric Acid | 4 | 2021 | 29 | 0.400 |
Why?
|
| Age Factors | 8 | 2019 | 1139 | 0.400 |
Why?
|
| Albuminuria | 5 | 2021 | 78 | 0.390 |
Why?
|
| Hypotension, Orthostatic | 1 | 2012 | 6 | 0.370 |
Why?
|
| Aged, 80 and over | 13 | 2020 | 2803 | 0.370 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2011 | 2 | 0.370 |
Why?
|
| Sodium Channel Blockers | 1 | 2011 | 18 | 0.360 |
Why?
|
| Sex Factors | 7 | 2019 | 1008 | 0.350 |
Why?
|
| Myocardial Contraction | 3 | 2022 | 46 | 0.350 |
Why?
|
| Kidney Failure, Chronic | 4 | 2015 | 239 | 0.350 |
Why?
|
| Mutation | 2 | 2016 | 1169 | 0.340 |
Why?
|
| Kidney Diseases | 3 | 2009 | 170 | 0.340 |
Why?
|
| Xanthine Oxidase | 2 | 2022 | 9 | 0.340 |
Why?
|
| Heart Atria | 3 | 2023 | 28 | 0.330 |
Why?
|
| Polysomnography | 5 | 2022 | 41 | 0.330 |
Why?
|
| Incidence | 9 | 2019 | 1054 | 0.310 |
Why?
|
| Enzyme Inhibitors | 1 | 2011 | 457 | 0.310 |
Why?
|
| Ventricular Remodeling | 3 | 2023 | 58 | 0.310 |
Why?
|
| Allopurinol | 2 | 2021 | 13 | 0.300 |
Why?
|
| Consensus | 2 | 2019 | 53 | 0.300 |
Why?
|
| Case-Control Studies | 10 | 2019 | 1266 | 0.300 |
Why?
|
| Societies, Medical | 3 | 2019 | 74 | 0.300 |
Why?
|
| Glomerular Filtration Rate | 4 | 2021 | 144 | 0.290 |
Why?
|
| Predictive Value of Tests | 7 | 2023 | 438 | 0.290 |
Why?
|
| Sympathectomy | 3 | 2016 | 11 | 0.280 |
Why?
|
| Hydrocortisone | 3 | 2017 | 89 | 0.280 |
Why?
|
| Renal Artery Obstruction | 4 | 2009 | 5 | 0.280 |
Why?
|
| Proteinuria | 1 | 2007 | 55 | 0.280 |
Why?
|
| DNA, Mitochondrial | 3 | 2022 | 185 | 0.270 |
Why?
|
| Terminology as Topic | 2 | 2019 | 40 | 0.270 |
Why?
|
| Hospitals, University | 2 | 2019 | 39 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2014 | 1112 | 0.270 |
Why?
|
| Electrocardiography | 3 | 2018 | 184 | 0.270 |
Why?
|
| Phenotype | 4 | 2019 | 774 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2016 | 358 | 0.260 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2020 | 37 | 0.260 |
Why?
|
| Clinical Trials as Topic | 4 | 2016 | 249 | 0.260 |
Why?
|
| Recurrence | 1 | 2007 | 149 | 0.250 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 522 | 0.250 |
Why?
|
| Myocardial Ischemia | 3 | 2016 | 82 | 0.250 |
Why?
|
| Amiloride | 2 | 2018 | 19 | 0.250 |
Why?
|
| Pheochromocytoma | 2 | 2020 | 12 | 0.250 |
Why?
|
| Disease Outbreaks | 1 | 2007 | 169 | 0.250 |
Why?
|
| Alabama | 4 | 2015 | 52 | 0.250 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2018 | 43 | 0.250 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2020 | 19 | 0.240 |
Why?
|
| Adolescent | 12 | 2021 | 5950 | 0.240 |
Why?
|
| Hypokalemia | 3 | 2012 | 11 | 0.240 |
Why?
|
| Vasodilation | 2 | 2014 | 64 | 0.240 |
Why?
|
| Stroke Volume | 3 | 2012 | 122 | 0.240 |
Why?
|
| Systole | 5 | 2020 | 67 | 0.230 |
Why?
|
| Body Mass Index | 6 | 2019 | 916 | 0.230 |
Why?
|
| Drug Combinations | 3 | 2009 | 102 | 0.220 |
Why?
|
| Patient Compliance | 4 | 2014 | 225 | 0.220 |
Why?
|
| Hemorheology | 1 | 2004 | 25 | 0.220 |
Why?
|
| Staphylococcus | 1 | 2004 | 8 | 0.220 |
Why?
|
| Urease | 1 | 2004 | 16 | 0.210 |
Why?
|
| Animals | 10 | 2019 | 16695 | 0.210 |
Why?
|
| Drug Chronotherapy | 2 | 2015 | 2 | 0.210 |
Why?
|
| Kidney Function Tests | 2 | 2015 | 30 | 0.210 |
Why?
|
| Weight Gain | 1 | 2004 | 138 | 0.210 |
Why?
|
| Exercise | 3 | 2020 | 674 | 0.210 |
Why?
|
| Cohort Studies | 4 | 2019 | 1729 | 0.200 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2014 | 96 | 0.200 |
Why?
|
| Cross-Over Studies | 5 | 2021 | 112 | 0.200 |
Why?
|
| Survival Rate | 5 | 2015 | 353 | 0.200 |
Why?
|
| Defibrillators, Implantable | 2 | 2018 | 39 | 0.200 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 577 | 0.190 |
Why?
|
| Young Adult | 11 | 2021 | 4936 | 0.190 |
Why?
|
| Aging | 1 | 2007 | 764 | 0.190 |
Why?
|
| Renal Circulation | 1 | 2002 | 20 | 0.190 |
Why?
|
| Potassium | 3 | 2020 | 109 | 0.180 |
Why?
|
| Hyperkalemia | 2 | 2012 | 13 | 0.180 |
Why?
|
| Creatinine | 3 | 2013 | 102 | 0.180 |
Why?
|
| Uricosuric Agents | 1 | 2021 | 1 | 0.180 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 236 | 0.180 |
Why?
|
| Drug Administration Schedule | 5 | 2014 | 153 | 0.180 |
Why?
|
| Natriuretic Peptide, Brain | 3 | 2013 | 19 | 0.180 |
Why?
|
| Diet | 4 | 2019 | 810 | 0.170 |
Why?
|
| Kidney Transplantation | 1 | 2002 | 102 | 0.170 |
Why?
|
| Lisinopril | 3 | 2016 | 4 | 0.170 |
Why?
|
| Enzyme Stability | 1 | 2020 | 35 | 0.170 |
Why?
|
| Epinephrine | 1 | 2020 | 37 | 0.170 |
Why?
|
| Adrenal Glands | 1 | 2020 | 17 | 0.170 |
Why?
|
| Electric Stimulation Therapy | 2 | 2018 | 17 | 0.160 |
Why?
|
| Glycosylation | 1 | 2020 | 111 | 0.160 |
Why?
|
| Sphygmomanometers | 1 | 2020 | 2 | 0.160 |
Why?
|
| Catalytic Domain | 1 | 2020 | 118 | 0.160 |
Why?
|
| Mutation, Missense | 1 | 2020 | 88 | 0.160 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 273 | 0.160 |
Why?
|
| Hot Temperature | 1 | 2020 | 141 | 0.160 |
Why?
|
| Multivariate Analysis | 5 | 2015 | 638 | 0.160 |
Why?
|
| Sympatholytics | 1 | 2019 | 13 | 0.150 |
Why?
|
| Chromatography, Liquid | 1 | 2020 | 173 | 0.150 |
Why?
|
| Water-Electrolyte Balance | 1 | 2019 | 17 | 0.150 |
Why?
|
| Hypernatremia | 1 | 2019 | 10 | 0.150 |
Why?
|
| Postoperative Complications | 1 | 2020 | 253 | 0.150 |
Why?
|
| Hypoglossal Nerve | 1 | 2018 | 10 | 0.140 |
Why?
|
| Postoperative Period | 1 | 2018 | 33 | 0.140 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2020 | 230 | 0.140 |
Why?
|
| Sympathomimetics | 1 | 2017 | 9 | 0.140 |
Why?
|
| Aortic Valve | 1 | 2018 | 38 | 0.140 |
Why?
|
| Mitral Valve | 1 | 2018 | 37 | 0.140 |
Why?
|
| Pharmacogenetics | 2 | 2008 | 63 | 0.140 |
Why?
|
| Accidental Falls | 1 | 2018 | 31 | 0.140 |
Why?
|
| Hemodynamics | 1 | 2018 | 101 | 0.140 |
Why?
|
| Alcohol Drinking | 4 | 2019 | 585 | 0.140 |
Why?
|
| Nutrition Surveys | 3 | 2019 | 263 | 0.140 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 37 | 0.140 |
Why?
|
| Gene Dosage | 1 | 2017 | 75 | 0.140 |
Why?
|
| Drug Interactions | 2 | 2009 | 151 | 0.140 |
Why?
|
| Cortisone | 1 | 2017 | 3 | 0.140 |
Why?
|
| Analysis of Variance | 1 | 2019 | 574 | 0.130 |
Why?
|
| Calcium Channel Blockers | 2 | 2007 | 57 | 0.130 |
Why?
|
| Health Behavior | 2 | 2019 | 568 | 0.130 |
Why?
|
| Gout Suppressants | 1 | 2016 | 5 | 0.130 |
Why?
|
| Publishing | 1 | 2017 | 28 | 0.130 |
Why?
|
| Diabetes Mellitus | 4 | 2015 | 532 | 0.130 |
Why?
|
| Hyperuricemia | 1 | 2016 | 13 | 0.130 |
Why?
|
| Mass Screening | 2 | 2014 | 531 | 0.130 |
Why?
|
| Cause of Death | 2 | 2014 | 183 | 0.130 |
Why?
|
| Blood Pressure Monitors | 1 | 2016 | 1 | 0.130 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 471 | 0.120 |
Why?
|
| Editorial Policies | 1 | 2016 | 14 | 0.120 |
Why?
|
| Geography | 2 | 2013 | 107 | 0.120 |
Why?
|
| Losartan | 2 | 2008 | 35 | 0.120 |
Why?
|
| Normetanephrine | 1 | 2015 | 3 | 0.120 |
Why?
|
| Cardiography, Impedance | 1 | 2015 | 4 | 0.120 |
Why?
|
| Competitive Behavior | 1 | 2015 | 15 | 0.120 |
Why?
|
| Haplotypes | 1 | 2016 | 197 | 0.120 |
Why?
|
| Industrial Microbiology | 1 | 2015 | 5 | 0.120 |
Why?
|
| Vascular Resistance | 1 | 2015 | 37 | 0.120 |
Why?
|
| Pichia | 1 | 2015 | 10 | 0.120 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 22 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 138 | 0.110 |
Why?
|
| COS Cells | 1 | 2015 | 67 | 0.110 |
Why?
|
| Proportional Hazards Models | 5 | 2016 | 512 | 0.110 |
Why?
|
| Reference Values | 3 | 2010 | 207 | 0.110 |
Why?
|
| Receptors, Glucagon | 1 | 2014 | 1 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2016 | 181 | 0.110 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2014 | 5 | 0.110 |
Why?
|
| Glucagon-Like Peptides | 1 | 2014 | 5 | 0.110 |
Why?
|
| Waist Circumference | 2 | 2013 | 90 | 0.110 |
Why?
|
| Physicians | 1 | 2016 | 180 | 0.110 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 427 | 0.110 |
Why?
|
| Cognition | 2 | 2015 | 458 | 0.100 |
Why?
|
| Carbolines | 1 | 2013 | 17 | 0.100 |
Why?
|
| Single-Blind Method | 2 | 2013 | 53 | 0.100 |
Why?
|
| Sodium Channels | 1 | 2014 | 66 | 0.100 |
Why?
|
| DNA Damage | 1 | 2016 | 358 | 0.100 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 293 | 0.100 |
Why?
|
| Congresses as Topic | 2 | 2014 | 49 | 0.100 |
Why?
|
| Self Care | 1 | 2014 | 173 | 0.100 |
Why?
|
| Population Groups | 1 | 2013 | 59 | 0.100 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 1020 | 0.100 |
Why?
|
| Vitamin D | 1 | 2014 | 196 | 0.100 |
Why?
|
| Risk | 2 | 2010 | 289 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 1188 | 0.090 |
Why?
|
| Disease Progression | 1 | 2015 | 661 | 0.090 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 1058 | 0.090 |
Why?
|
| Kidney Medulla | 1 | 2011 | 6 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1559 | 0.090 |
Why?
|
| Ethanolamines | 1 | 2011 | 9 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2018 | 238 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 41 | 0.090 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2011 | 27 | 0.090 |
Why?
|
| Community Health Services | 1 | 2013 | 207 | 0.090 |
Why?
|
| Benzopyrans | 1 | 2011 | 25 | 0.090 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2011 | 16 | 0.090 |
Why?
|
| Hormones | 1 | 2011 | 56 | 0.090 |
Why?
|
| Anthropometry | 1 | 2011 | 96 | 0.090 |
Why?
|
| Angiotensinogen | 1 | 2011 | 6 | 0.090 |
Why?
|
| Drug Therapy | 1 | 2011 | 17 | 0.090 |
Why?
|
| Universities | 1 | 2015 | 539 | 0.090 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2011 | 35 | 0.090 |
Why?
|
| Motivation | 1 | 2015 | 492 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 602 | 0.090 |
Why?
|
| Dementia | 1 | 2012 | 155 | 0.090 |
Why?
|
| Salts | 1 | 2010 | 18 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 55 | 0.090 |
Why?
|
| Regression Analysis | 2 | 2011 | 487 | 0.090 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2011 | 74 | 0.090 |
Why?
|
| Biomedical Research | 1 | 2016 | 467 | 0.080 |
Why?
|
| Genetic Loci | 1 | 2011 | 102 | 0.080 |
Why?
|
| Chronobiology Disorders | 1 | 2010 | 4 | 0.080 |
Why?
|
| Cognition Disorders | 1 | 2012 | 243 | 0.080 |
Why?
|
| Brachial Artery | 2 | 2014 | 27 | 0.080 |
Why?
|
| Endothelial Cells | 1 | 2013 | 324 | 0.080 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 200 | 0.080 |
Why?
|
| Adipocytes | 1 | 2010 | 58 | 0.080 |
Why?
|
| Pituitary ACTH Hypersecretion | 1 | 2009 | 2 | 0.080 |
Why?
|
| Age of Onset | 1 | 2010 | 115 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 57 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2009 | 24 | 0.080 |
Why?
|
| Spain | 2 | 2019 | 43 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2008 | 11 | 0.070 |
Why?
|
| Heart | 1 | 2010 | 181 | 0.070 |
Why?
|
| Dyslipidemias | 1 | 2009 | 48 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 37 | 0.070 |
Why?
|
| C-Reactive Protein | 2 | 2021 | 164 | 0.070 |
Why?
|
| Natriuresis | 1 | 2007 | 11 | 0.070 |
Why?
|
| Angiotensin II | 2 | 2012 | 103 | 0.070 |
Why?
|
| Depression | 1 | 2014 | 837 | 0.070 |
Why?
|
| Fumarates | 1 | 2007 | 11 | 0.070 |
Why?
|
| Decision Trees | 1 | 2006 | 22 | 0.070 |
Why?
|
| Respiratory Function Tests | 1 | 2007 | 61 | 0.060 |
Why?
|
| Logistic Models | 3 | 2014 | 1001 | 0.060 |
Why?
|
| Ventricular Fibrillation | 1 | 2005 | 9 | 0.060 |
Why?
|
| Tachycardia, Ventricular | 1 | 2005 | 14 | 0.060 |
Why?
|
| Radioimmunoassay | 1 | 2005 | 70 | 0.060 |
Why?
|
| Japan | 1 | 2006 | 348 | 0.060 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2005 | 39 | 0.060 |
Why?
|
| Chronic Disease | 1 | 2008 | 541 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2015 | 162 | 0.060 |
Why?
|
| Hyperemia | 1 | 2004 | 3 | 0.060 |
Why?
|
| Thermogenesis | 1 | 2004 | 24 | 0.060 |
Why?
|
| Bacteriolysis | 1 | 2004 | 2 | 0.050 |
Why?
|
| Brain | 1 | 2012 | 1452 | 0.050 |
Why?
|
| Acrylic Resins | 1 | 2004 | 12 | 0.050 |
Why?
|
| Statistics as Topic | 2 | 2016 | 123 | 0.050 |
Why?
|
| Chromatography, Gel | 1 | 2004 | 52 | 0.050 |
Why?
|
| Ammonia | 1 | 2004 | 22 | 0.050 |
Why?
|
| Hemochromatosis | 1 | 2004 | 3 | 0.050 |
Why?
|
| Durapatite | 1 | 2004 | 18 | 0.050 |
Why?
|
| Atrial Function, Left | 1 | 2023 | 3 | 0.050 |
Why?
|
| Molecular Weight | 1 | 2004 | 168 | 0.050 |
Why?
|
| Urea | 1 | 2004 | 44 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2015 | 224 | 0.050 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2004 | 32 | 0.050 |
Why?
|
| Age Distribution | 2 | 2015 | 249 | 0.050 |
Why?
|
| Ultrasonography | 1 | 2004 | 132 | 0.050 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 198 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 93 | 0.050 |
Why?
|
| Torsion, Mechanical | 2 | 2014 | 4 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 733 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2004 | 90 | 0.050 |
Why?
|
| Verapamil | 1 | 2002 | 7 | 0.050 |
Why?
|
| Enalapril | 1 | 2002 | 7 | 0.050 |
Why?
|
| Lactones | 1 | 2002 | 22 | 0.050 |
Why?
|
| Anti-Obesity Agents | 1 | 2002 | 11 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2005 | 199 | 0.050 |
Why?
|
| Receptors, Angiotensin | 1 | 2002 | 15 | 0.050 |
Why?
|
| Kinetics | 1 | 2004 | 698 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2004 | 230 | 0.050 |
Why?
|
| Blood Vessels | 1 | 2002 | 36 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2015 | 336 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 236 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 458 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 10 | 0.040 |
Why?
|
| Gout | 1 | 2021 | 16 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2004 | 336 | 0.040 |
Why?
|
| Veterans | 1 | 2003 | 203 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2016 | 362 | 0.040 |
Why?
|
| California | 2 | 2013 | 531 | 0.040 |
Why?
|
| Patient Positioning | 1 | 2020 | 4 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2020 | 37 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2002 | 278 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2004 | 548 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 93 | 0.040 |
Why?
|
| Motor Activity | 2 | 2014 | 438 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 14 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 114 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 246 | 0.040 |
Why?
|
| Mississippi | 1 | 2019 | 129 | 0.040 |
Why?
|
| Smoking | 2 | 2019 | 1019 | 0.040 |
Why?
|
| Mitochondria | 1 | 2022 | 516 | 0.040 |
Why?
|
| NADH Dehydrogenase | 1 | 2017 | 6 | 0.030 |
Why?
|
| Electron Transport Complex III | 1 | 2017 | 13 | 0.030 |
Why?
|
| Least-Squares Analysis | 2 | 2008 | 45 | 0.030 |
Why?
|
| Vasculitis | 1 | 2016 | 4 | 0.030 |
Why?
|
| Oscillometry | 1 | 2016 | 9 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2016 | 88 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2016 | 990 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 18 | 0.030 |
Why?
|
| Triamterene | 1 | 2016 | 1 | 0.030 |
Why?
|
| Policy Making | 1 | 2016 | 35 | 0.030 |
Why?
|
| Algorithms | 2 | 2009 | 508 | 0.030 |
Why?
|
| Fluorometry | 1 | 2016 | 17 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2016 | 63 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 176 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 137 | 0.030 |
Why?
|
| Genotype | 2 | 2011 | 796 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2015 | 116 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2015 | 43 | 0.030 |
Why?
|
| Dipyridamole | 1 | 2014 | 4 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 1221 | 0.030 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2014 | 6 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2014 | 35 | 0.030 |
Why?
|
| Social Class | 1 | 2016 | 286 | 0.030 |
Why?
|
| Vomiting | 1 | 2014 | 14 | 0.030 |
Why?
|
| Nausea | 1 | 2014 | 13 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 55 | 0.030 |
Why?
|
| Biological Availability | 1 | 2014 | 115 | 0.030 |
Why?
|
| Research Design | 1 | 2016 | 370 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1541 | 0.030 |
Why?
|
| Potassium, Dietary | 1 | 2014 | 1 | 0.030 |
Why?
|
| Medicare | 1 | 2017 | 326 | 0.030 |
Why?
|
| Nitrites | 1 | 2013 | 54 | 0.030 |
Why?
|
| Diarrhea | 1 | 2014 | 95 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 2013 | 55 | 0.030 |
Why?
|
| Amine Oxidase (Copper-Containing) | 1 | 2013 | 5 | 0.030 |
Why?
|
| Antigens, CD34 | 1 | 2013 | 19 | 0.030 |
Why?
|
| Echocardiography | 1 | 2014 | 167 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2013 | 109 | 0.030 |
Why?
|
| Cell Count | 1 | 2013 | 140 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 84 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 34 | 0.020 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 90 | 0.020 |
Why?
|
| Brazil | 1 | 2012 | 83 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 181 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1516 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2012 | 25 | 0.020 |
Why?
|
| Renal Artery | 1 | 2012 | 7 | 0.020 |
Why?
|
| Baroreflex | 1 | 2012 | 10 | 0.020 |
Why?
|
| Furosemide | 1 | 2011 | 10 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 90 | 0.020 |
Why?
|
| Dinoprost | 1 | 2011 | 22 | 0.020 |
Why?
|
| Executive Function | 1 | 2012 | 55 | 0.020 |
Why?
|
| Organ Size | 1 | 2011 | 167 | 0.020 |
Why?
|
| Linear Models | 1 | 2012 | 311 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2011 | 58 | 0.020 |
Why?
|
| Adaptation, Physiological | 1 | 2012 | 135 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2011 | 146 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 203 | 0.020 |
Why?
|
| Environment | 1 | 2011 | 148 | 0.020 |
Why?
|
| Observer Variation | 1 | 2009 | 58 | 0.020 |
Why?
|
| Diet, Reducing | 1 | 2009 | 23 | 0.020 |
Why?
|
| Educational Status | 1 | 2010 | 335 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 174 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2008 | 41 | 0.020 |
Why?
|
| Counseling | 1 | 2009 | 134 | 0.020 |
Why?
|
| Inflammation | 1 | 2013 | 729 | 0.020 |
Why?
|
| Software | 1 | 2009 | 234 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 89 | 0.020 |
Why?
|
| Medication Errors | 1 | 2007 | 7 | 0.020 |
Why?
|
| Contraceptives, Oral | 1 | 2007 | 17 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2007 | 23 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2014 | 583 | 0.020 |
Why?
|
| Amides | 1 | 2007 | 72 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2007 | 189 | 0.020 |
Why?
|
| Erythrocyte Membrane | 1 | 2005 | 20 | 0.010 |
Why?
|
| Waist-Hip Ratio | 1 | 2005 | 34 | 0.010 |
Why?
|
| Exercise Test | 1 | 2005 | 75 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2005 | 99 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2013 | 2111 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2005 | 208 | 0.010 |
Why?
|
| Angiography | 1 | 2003 | 15 | 0.010 |
Why?
|
| Insulin | 1 | 2005 | 255 | 0.010 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2002 | 12 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2005 | 386 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 113 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 141 | 0.010 |
Why?
|
| Hydrolases | 1 | 2002 | 15 | 0.010 |
Why?
|
| Okadaic Acid | 1 | 2002 | 14 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2002 | 72 | 0.010 |
Why?
|
| Acid Phosphatase | 1 | 2002 | 23 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 428 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 37 | 0.010 |
Why?
|
| Glucuronidase | 1 | 2002 | 21 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 162 | 0.010 |
Why?
|
| Ceramides | 1 | 2002 | 43 | 0.010 |
Why?
|
| Lysosomes | 1 | 2002 | 88 | 0.010 |
Why?
|
| Lipids | 1 | 2002 | 256 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 379 | 0.010 |
Why?
|